Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Accenture
Moodys
Julphar
Boehringer Ingelheim
UBS
Covington
Mallinckrodt
Fish and Richardson
Johnson and Johnson

Generated: August 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Method of treating cognitive impairments and schizophrenias
Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s): Jordan; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., LTD. (Tokyo, JP)
Application Number:13/303,265
Patent Claims: 1. A method of treating a patient suffering from treatment-resistant schizophrenia, comprising administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof: ##STR00003## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond, wherein the patient is a mammal and the patient fails to respond adequately to antipsychotic drugs which are at least one typical antipsychotic drug and at least one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.

2. The method of claim 1, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine.

3. The method of claim 1, wherein the at least one typical antipsychotic drug comprises one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol.

4. The method of claim 1, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine and haloperidol.

5. The method according to any one of claims 1, 2, 3, and 4, wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril- .

6. A method of treating a patient suffering from treatment-resistant schizophrenia with cognitive impairments, comprising administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof: ##STR00004## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond, wherein the patient is a mammal and the patient fails to respond adequately to antipsychotic drugs which are at least one typical antipsychotic drug and at least one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride.

7. The method of claim 6, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine.

8. The method of claim 6, wherein the at least one typical antipsychotic drug comprises one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol.

9. The method of claim 6, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine and haloperidol.

10. The method according to any one of claims 6-9, wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril- .
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Covington
Chinese Patent Office
Medtronic
Baxter
Dow
Cipla
US Department of Justice
Daiichi Sankyo
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot